FR3008315A1 - Composition topique cosmetique protectrice vis-a-vis des xenobiotiques - Google Patents
Composition topique cosmetique protectrice vis-a-vis des xenobiotiques Download PDFInfo
- Publication number
- FR3008315A1 FR3008315A1 FR1356808A FR1356808A FR3008315A1 FR 3008315 A1 FR3008315 A1 FR 3008315A1 FR 1356808 A FR1356808 A FR 1356808A FR 1356808 A FR1356808 A FR 1356808A FR 3008315 A1 FR3008315 A1 FR 3008315A1
- Authority
- FR
- France
- Prior art keywords
- skin
- composition
- polyurethane
- composition according
- spray
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 230000000699 topical effect Effects 0.000 title claims abstract description 7
- 239000002537 cosmetic Substances 0.000 title claims abstract description 6
- 230000001681 protective effect Effects 0.000 title claims description 25
- 239000002676 xenobiotic agent Substances 0.000 title claims description 11
- 229920002635 polyurethane Polymers 0.000 claims abstract description 19
- 239000004814 polyurethane Substances 0.000 claims abstract description 19
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 8
- 241000220215 Moringa Species 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 239000007921 spray Substances 0.000 claims description 27
- 230000002285 radioactive effect Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 7
- 230000018044 dehydration Effects 0.000 claims description 6
- 238000006297 dehydration reaction Methods 0.000 claims description 6
- 230000002034 xenobiotic effect Effects 0.000 claims description 3
- 244000179886 Moringa oleifera Species 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 description 59
- 210000000434 stratum corneum Anatomy 0.000 description 17
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 14
- 230000004888 barrier function Effects 0.000 description 13
- 210000002615 epidermis Anatomy 0.000 description 12
- 230000035515 penetration Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000036571 hydration Effects 0.000 description 9
- 238000006703 hydration reaction Methods 0.000 description 9
- 229920000742 Cotton Polymers 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 7
- 230000003020 moisturizing effect Effects 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 210000004207 dermis Anatomy 0.000 description 6
- 239000004909 Moisturizer Substances 0.000 description 5
- 239000006229 carbon black Substances 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 210000000245 forearm Anatomy 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000001333 moisturizer Effects 0.000 description 5
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000003344 environmental pollutant Substances 0.000 description 3
- 230000009931 harmful effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 231100000719 pollutant Toxicity 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 229940073669 ceteareth 20 Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000736 corneocyte Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 231100000507 endocrine disrupting Toxicity 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003780 keratinization Effects 0.000 description 2
- 229940057874 phenyl trimethicone Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910052713 technetium Inorganic materials 0.000 description 2
- 229940056501 technetium 99m Drugs 0.000 description 2
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 2
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 241000238582 Artemia Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940057871 hydrogenated palm glycerides Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 150000004045 organic chlorine compounds Chemical class 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/87—Polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (11)
- REVENDICATIONS1/ Composition cosmétique topique protectrice vis-à-vis des xénobiotiques caractérisée en ce qu'elle contient, en tant qu'actif, en combinaison, du polyuréthane et un extrait de moringa.
- 2/ Composition selon la revendication 1, caractérisée en ce que l'extrait est un extrait de graine de Moringa pterygosperma.
- 3/ Composition selon l'une des revendications précédentes, caractérisée en ce que l'extrait représente entre 1 et 5% en poids de la composition.
- 4/ Composition selon l'une des revendications précédentes, caractérisée en ce que le polyuréthane représente avantageusement 2 à 10% en poids de la composition.
- 5/ Composition selon l'une des revendications précédentes, caractérisée en ce le polyuréthane se présente sous la forme d'un mélange de polyuréthane 34 (PU-34) et de polyuréthane 35 (PU-35).
- 6/ Composition selon la revendication 5, caractérisée en ce que le polyuréthane 34 (PU- 34) et de polyuréthane 35 (PU-35) sont en proportion égale.
- 7/ Composition selon l'une des revendications précédentes, caractérisée en ce qu'elle contient un extrait de Moringa, représentant avantageusement entre 1 et 5% en poids de la composition.
- 8/ Composition selon l'une des revendications précédentes, caractérisée en ce qu'elle contient une huile de silicone représentant avantageusement entre 2 et 15% en poids de la composition.
- 9/ Composition selon l'une des revendications précédentes, caractérisée en ce qu'elle se présente sous la forme d'un spray.
- 10/ Procédé visant à protéger la peau des xénobiotiques et de la déshydratation, consistant à appliquer la composition topique objet de l'une des revendications 1 à 9 sur la peau puis à laisser sécher la peau.
- 11/ Procédé selon la revendication 10, caractérisé en ce que le xénobiotique est un composant radioactif40
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1356808A FR3008315B1 (fr) | 2013-07-11 | 2013-07-11 | Composition topique cosmetique protectrice vis-a-vis des xenobiotiques |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1356808A FR3008315B1 (fr) | 2013-07-11 | 2013-07-11 | Composition topique cosmetique protectrice vis-a-vis des xenobiotiques |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3008315A1 true FR3008315A1 (fr) | 2015-01-16 |
FR3008315B1 FR3008315B1 (fr) | 2020-07-24 |
Family
ID=49474592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1356808A Active FR3008315B1 (fr) | 2013-07-11 | 2013-07-11 | Composition topique cosmetique protectrice vis-a-vis des xenobiotiques |
Country Status (1)
Country | Link |
---|---|
FR (1) | FR3008315B1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108125848A (zh) * | 2017-11-30 | 2018-06-08 | 东莞沃莱施日用品有限公司 | 一种沐浴露及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2776519A1 (fr) * | 1998-03-24 | 1999-10-01 | Serobiologiques Lab Sa | Utilisation d'au moins un extrait proteique de graines de plantes du genre moringa et composition cosmetique et/ou pharmaceutique correspondante |
WO2002096448A1 (fr) * | 2001-05-29 | 2002-12-05 | Philippe Jean Louis Thurot | Composition pour l'hygiene buccale ou corporelle ou pour la sante comprenant des graines ou un broyat ou un extrait proteinique de graines d'une plante du genre moringa |
WO2003011234A1 (fr) * | 2001-07-27 | 2003-02-13 | International Flora Technologies, Ltd. | Composition ultra-stable comprenant de l'huile de ben, ses derives et ses utilisations |
US20060275247A1 (en) * | 2005-06-01 | 2006-12-07 | Revlon Consumer Products Corporation | Cosmetic Compositions With Moringa Seed Extract |
WO2007068331A1 (fr) * | 2005-12-13 | 2007-06-21 | Henkel Kommanditgesellschaft Auf Aktien | Agent de traitement capillaire contenant des extraits vegetaux et une protection contre les uv |
FR2946879A1 (fr) * | 2009-06-22 | 2010-12-24 | Fabre Pierre Dermo Cosmetique | Extrait de graines entieres de moringa sp. et son utilisation dans des compositions cosmetiques et/ou dermatologiques. |
-
2013
- 2013-07-11 FR FR1356808A patent/FR3008315B1/fr active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2776519A1 (fr) * | 1998-03-24 | 1999-10-01 | Serobiologiques Lab Sa | Utilisation d'au moins un extrait proteique de graines de plantes du genre moringa et composition cosmetique et/ou pharmaceutique correspondante |
WO2002096448A1 (fr) * | 2001-05-29 | 2002-12-05 | Philippe Jean Louis Thurot | Composition pour l'hygiene buccale ou corporelle ou pour la sante comprenant des graines ou un broyat ou un extrait proteinique de graines d'une plante du genre moringa |
WO2003011234A1 (fr) * | 2001-07-27 | 2003-02-13 | International Flora Technologies, Ltd. | Composition ultra-stable comprenant de l'huile de ben, ses derives et ses utilisations |
US20060275247A1 (en) * | 2005-06-01 | 2006-12-07 | Revlon Consumer Products Corporation | Cosmetic Compositions With Moringa Seed Extract |
WO2007068331A1 (fr) * | 2005-12-13 | 2007-06-21 | Henkel Kommanditgesellschaft Auf Aktien | Agent de traitement capillaire contenant des extraits vegetaux et une protection contre les uv |
FR2946879A1 (fr) * | 2009-06-22 | 2010-12-24 | Fabre Pierre Dermo Cosmetique | Extrait de graines entieres de moringa sp. et son utilisation dans des compositions cosmetiques et/ou dermatologiques. |
Non-Patent Citations (2)
Title |
---|
DATABASE GNPD [online] MINTEL; 1 April 2011 (2011-04-01), "Vital Defense Antioxidant Anti-Pollution Hydration Cream", XP002721390, Database accession no. 1546783 * |
DATABASE GNPD [online] MINTEL; 1 March 2011 (2011-03-01), "Anti-Pollution care Face Cleansing Foam", XP002721391, Database accession no. 1500317 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108125848A (zh) * | 2017-11-30 | 2018-06-08 | 东莞沃莱施日用品有限公司 | 一种沐浴露及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
FR3008315B1 (fr) | 2020-07-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Escobar-Chavez et al. | The tape-stripping technique as a method for drug quantification in skin | |
Klimová et al. | Skin absorption and human exposure estimation of three widely discussed UV filters in sunscreens–In vitro study mimicking real-life consumer habits | |
Pople et al. | Development and evaluation of colloidal modified nanolipid carrier: Application to topical delivery of tacrolimus, Part II–In vivo assessment, drug targeting, efficacy, and safety in treatment for atopic dermatitis | |
de Souza de Bustamante Monteiro et al. | Evaluation of octyl p-methoxycinnamate included in liposomes and cyclodextrins in anti-solar preparations: preparations, characterizations and in vitro penetration studies | |
EP3664769A2 (fr) | Emulsion moussante a haute teneur en huile et ses utilisations, notamment pour l'hygiene corporelle | |
WO2001021150A1 (fr) | Utilisation d'un produit d'huile vegetale en tant qu'agent pour augmenter la synthese des lipides cutanes | |
KR101500191B1 (ko) | 피부 케어용 조성물 및 이의 제조 방법 | |
EP2907498A1 (fr) | Perles de cellulose exfoliante et leurs utilisations cosmétiques | |
Jeong et al. | Comparison of the efficacy of Atopalm® multi-lamellar emulsion cream and Physiogel® intensive cream in improving epidermal permeability barrier in sensitive skin | |
Darlenski et al. | In vivo Raman confocal spectroscopy in the investigation of the skin barrier | |
KR102134930B1 (ko) | 화장료 조성물의 피부 미백 효과 평가 방법 | |
JP2010271163A (ja) | 皮膚状態の評価方法 | |
Khan et al. | Anti-aging effects of Hippophae rhamnoides emulsion on human skin | |
JP6326557B1 (ja) | 被験物質又は物品が皮膚に与える影響を評価する方法 | |
Li et al. | Effect of 1, 4-cyclohexanediol on percutaneous absorption and penetration of azelaic acid | |
FR3008315A1 (fr) | Composition topique cosmetique protectrice vis-a-vis des xenobiotiques | |
Li et al. | Synergistic effect of 1, 4-cyclohexanediol and 1, 2-hexanediol on percutaneous absorption and penetration of metronidazole | |
KR101857282B1 (ko) | 패 추출물을 포함하는 화장료 조성물 | |
Brulos et al. | Influence of perfumes on the sensitizing potential of cosmetic bases. 1. A technique for evaluating sensitizing potential | |
EP1641433A1 (fr) | Nouvelles compositions dermatologiques et/ou cosmetologiques hydratantes et anti-irritantes | |
Khan et al. | Hippophae rhamnoides oil-in-water (O/W) emulsion improves barrier function in healthy human subjects | |
FR3008313A1 (fr) | Composition topique cosmetique protectrice vis-a-vis des xenobiotiques | |
Sundar et al. | Preparation and optimization of medicated cold cream using Caralluma adscendens var. attenuata for the treatment of Candida skin infection | |
Buszewska-Forajta et al. | Studies of the effect of grasshopper abdominal secretion on wound healing with the use of murine model | |
Jung et al. | Comparative study on picryl chloride (PCL)-induced contact dermatitis in female IQI/Jic and BALB/c mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 3 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 6 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
PLFP | Fee payment |
Year of fee payment: 8 |
|
PLFP | Fee payment |
Year of fee payment: 9 |
|
PLFP | Fee payment |
Year of fee payment: 10 |
|
PLFP | Fee payment |
Year of fee payment: 11 |
|
AU | Other action affecting the ownership or exploitation of an industrial property right |
Effective date: 20231016 |
|
CL | Concession to grant licences |
Name of requester: NAOS, FR Effective date: 20231016 Name of requester: NAOS INSTITUTE OF LIFE SCIENCE, FR Effective date: 20231016 |